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ABSTRACT 
 
Objectives:  Non-melanoma skin cancers are the most frequently occurring type of cancer 
worldwide.  They can be effectively treated using topical dermatological photodynamic therapy 
(PDT) employing protoporphyrin IX (PpIX) as the active photosensitising agent as long as the disease 
remains superficial.  Novel iron chelating agents are being investigated to enhance the effectiveness 
and extend the applications of this treatment modality, as limiting free iron increases the 
accumulation of PpIX available for light activation and thus cell kill. 
 
Methods:  Human lung fibroblasts (MRC-5) and epithelial squamous carcinoma (A431) cells were 
treated with PpIX precursors (aminolaevulinic acid (ALA) or methyl-aminolevulinate (MAL)) with or 
without the separate hydroxypyridinone iron chelating agent (CP94) or alternatively, the new 
combined iron chelator and PpIX producing agent, AP2-18.  PpIX fluorescence was monitored hourly 
for 6 hours prior to irradiation.  PDT effectiveness was then assessed the following day using the 
lactate dehydrogenase and neutral red assays.   
 
Results:  Generally, iron chelation achieved via CP94 or AP2-18 administration significantly increased 
PpIX fluorescence.  ALA was more effective as a PpIX-prodrug than MAL in A431 cells, corresponding 
with the lower PpIX accumulation observed with the latter congener in this cell type.  Addition of 
either iron chelating agent consistently increased PpIX accumulation but did not always convey an 
extra beneficial effect on PpIX-PDT cell kill when using the already highly effective higher dose of 
ALA.  However, these adjuvants were highly beneficial in the skin cancer cells when compared with 
MAL administration alone.  AP2-18 was also at least as effective as CP94 + ALA/MAL co-
administration throughout and significantly better than CP94 supplementation at increasing PpIX 
fluorescence in MRC5 cells as well as at lower doses where PpIX accumulation was observed to be 
more limited.   
 
Conclusions:  PpIX fluorescence levels, as well as PDT cell kill effects on irradiation can be 
significantly increased by pyridinone iron chelation, either via the addition of CP94 to the 
administration of a PpIX precursor or alternatively via the newly synthesised combined PpIX prodrug 
and siderophore, AP2-18.  The effect of the latter compound appears to be at least equivalent to, if 
not better than, the separate administration of its constituent parts, particularly when employing 
MAL to destroy skin cancer cells.  AP2-18 therefore warrants further detailed analysis, as it may have 
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the potential to improve dermatological PDT outcomes in applications currently requiring 
enhancement. 
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INTRODUCTION 
 
Non-melanoma skin cancers (NMSC) are one of the most common types of cancer Worldwide [1-2].  
They are predominantly located on the face and neck, and can lead to local skin damage or 
disfigurement [3] if left untreated.  Although they are not associated with high mortality rates, they 
occur with high frequency [3] and their occurrence is increasing due to a rise in ultraviolet exposure, 
a causation factor [1,3-4].  They are mainly diagnosed in older Caucasians [3,5] but all age groups are 
at risk [4].  NMSC can be divided into basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) 
[3,5].  BCC is the most common NMSC and can either be classified as superficial (sBCC) or nodular 
(nBCC) [3].  SCC formation is thought to progress from pre-cancers like actinic keratosis and Bowen’s 
disease in a small number of cases [3,6].   
 
Traditionally, NMSCs have been surgically excised, treated with topical 5-fluorouracil application or 
frozen with cryotherapy [6-9].  However, these conventional therapies are not always associated 
with excellent cosmesis [6-9] and their appropriateness can be limited, depending on the location, 
size and number of NMSC lesions to be treated [9-11].  Alternative treatment options have therefore 
been sought.  Photodynamic therapy (PDT) is a relatively new, minimally invasive, light-induced drug 
treatment of certain forms of NMSC [5-11].  Dermatological PDT can be administered by nurses and 
is safe, with few side effects beyond treatment effects [7-8,10-12].  Several cancers, including NMSCs 
and pre-cancers can be treated using PDT [5-14].  It can also be used to treat some non-malignant 
skin diseases such as psoriasis and acne [15].  PDT has several advantages over some forms of 
traditional management, including the possibility of treating a whole area of field change at once, 
the occurrence of good healing on the lower leg, repeated application to the same area of the skin 
without the development of resistance, excellent cosmetic results in highly visible sites without the 
need for advanced surgical techniques and its compatibility as an adjuvant with other treatment 
approaches [5-15].  
 
PDT utilises a light-absorbing molecule (photosensitiser), activating light of a specific wavelength and 
molecular oxygen [16-18].  After absorbing energy from the light, the photosensitiser moves into 
higher energetic states and transfers this additional energy to molecular oxygen directly or indirectly 
via type II or type I photochemical reactions respectively [16-19].  These reactions form reactive 
oxygen species (ROS), which then damage cellular components like proteins, lipids and DNA or 
indeed the photosensitiser itself, inducing photobleaching [18-21].  The cellular cascades of ROS thus 
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generated, overwhelm the cell’s inherent antioxidant defense and ultimately lead to cell death via 
apoptosis and necrosis, or alternatively, a destructive form of autophagy [18-25].  
 
The photosensitiser most commonly used in dermatological PDT is protoporphyrin IX (PpIX) [10-11, 
13].  PpIX (a large, water-insoluble molecule) can be excited by light of wavelength 635 nm [26].  This 
light penetrates deeper into the tissue than shorter activating wavelengths [27].  Skin lesions are 
treated with a topical cream containing a small, soluble precursor to PpIX (e.g. 5-aminolaevulinic 
acid (ALA) or the methyl-ester of ALA, methyl-aminolevulinate; MAL)) [10-11].  This is absorbed by 
cells and enzymatically converted into light sensitive PpIX over a few hours (typically three in clinical 
application) by the haem biosynthesis pathway naturally present in all nucleated cells [10,26-27].  
This exogenous administration of copious amounts of PpIX precursor bypasses the primary rate 
limiting step of this pathway (the synthesis of ALA from glycine and succinyl-CoA by ALA synthase) 
[26-28].  This forces the rest of the pathway to operate at maximal capacity until PpIX (the 
immediate precursor to haem) is formed.  This naturally light sensitive compound starts to 
accumulate over time as the final step in the pathway (the insertion of Fe2+ into PpIX by 
ferrochelatase to form haem) is relatively slow to occur and is thus the secondary rate limiting step 
of this pathway [26-28].   
 
ALA-PDT was first introduced experimentally by Malik and Lugaci in 1987 [29], with the first clinical 
treatments reported by Kennedy and co-workers in 1990 [17].  It is particularly effective in cancer 
cells as PpIX accumulation is both lower and slower in normal cells, resulting in less damage to the 
healthy cells in close proximity to the diseased cells in the treatment area [26].  This occurs as haem 
biosynthesis is elevated and less well controlled in neoplastic cells and tumour cells also have an 
altered iron metabolism and dysregulated porphyrin biosynthesis enzymes, which makes them more 
prone to accumulate PpIX more rapidly [26,30-31].  The disrupted tumour surface is also more 
permeable than healthy skin, hence facilitating PpIX precursor penetration to where its treatment 
action is needed most [26,31].  
  
Although effective treatment outcomes associated with excellent cosmesis have been demonstrated 
in licensed dermatological lesions (actinic keratosis, Bowen’s disease and BCC) when the disease 
remains superficial [10,32], efforts continue to both increase the efficacy and extend the 
applications of dermatological PDT particularly in order to treat thicker or acrally located conditions 
[33].   It is already known that poor penetration into the deeper skin layers can be improved clinically 
by employing more lipophilic ALA derivatives (e.g. MAL; Metvix, Galderma, UK) [36-40] or 
6 
 
nanoemulsion formulations (e.g. ALA; Ameluz, Spirit Healthcare, UK) [32] and by performing skin 
pre-treatments like the removal of the outer skin layer by tape stripping or scraping [41-43].  In fact 
many adaptations to the standard treatment protocol have been considered to improve efficacy 
including skin pre-treatment with the malignant cell differentiation potentiator dimethyl sulfoxide 
[44], light dose fractionation [45-46], low fluence rate light administration [47] as well as 
combinations with other techniques (e.g. low dose Photofrin [48], hyperthermia [49,50], 
iontophoresis [51] and bioreductive drugs [52]).  Concurrent administration of an iron chelator 
during PpIX-PDT has also been demonstrated to increase cellular accumulation of PpIX [20,53-54].  
This approach works because once the PpIX has bound Fe2+ to form haem, it is no longer active for 
PDT and so by adding iron chelators to trap iron ions in combination with PpIX precursors, this 
competition can be undermined elevating PpIX accumulation and thus increasing cell kill on 
subsequent irradiation [55-56].  Iron chelation has now been reported as a method of enhancing 
PpIX-induced PDT using the iron chelating agents, ethylenediamine tetraacetic acid (EDTA) [41-
43,57], desferrioxamine (DFO; Desferal, Novartis, USA) [57, 58-61] and the novel hydroxypyridinone 
iron chelator CP94 [62-66].  This particular method of enhancement is attractive because it is a 
simple pharmacological modification, which requires no alteration to the licensed treatment 
protocol other than the addition of the iron chelator to the PpIX prodrug cream [12,67].  
 
CP94 (1,2-diethyl-3-hydroxypyridin-4-one hydrochloride) is a member of the hydroxypyridinone 
family of oral iron chelators originally developed to supersede DFO (which is a natural siderophore 
(iron carrier) that has to be administered intravenously clinically via long infusion) in the treatment 
of iron overload.  It is closely related to the clinically established oral iron chelating agent 
Deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one hydrochloride (CP20); Ferriprox, Swedish Orphan 
Biovitrum Ltd, Sweden) but CP94 was found to be superior to CP20 for this particular application 
(PpIX-PDT enhancement) in previous animal studies [65].  CP94 is particularly effective at chelating 
intracellular iron and has a lower molecular weight and higher lipophilicity than either DFO or EDTA 
[68] and is well suited to augmenting dermatological PDT as it can be applied topically [69].  CP94 
has already been demonstrated to enhance ALA-induced PpIX fluorescence [62] and to also produce 
greater tumour necrosis within animal models [65,66].  CP94 has been investigated in a healthy skin 
explant model producing increased PpIX accumulation when employing either ALA or MAL as the 
PpIX precursor [63].  When the level of PpIX accumulation produced by DFO and CP94 were 
compared directly in vitro [53], these iron chelators in combination with ALA or MAL were shown to 
significantly increase the amount of PpIX accumulating within fetal lung fibroblasts (MRC5) and the 
more difficult to culture squamous epidermal carcinoma cells (A431), whilst minimal enhancement 
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was observed in the normal skin fibroblasts (84BR) and keratinocytes (NHEK) investigated.  Where 
enhancement was observed, CP94 was consistently demonstrated to be significantly superior to DFO 
in the production of elevated PpIX levels [53] and it has already been established that DFO is 
superior to EDTA in its ability to enhance PpIX-induced PDT [57]. 
 
In clinical studies of iron chelator enhancement of PpIX-induced PDT, Fijan et al. [59] demonstrated 
the feasibility of combining the iron chelator DFO with ALA-PDT to treat 34 superficial and 22 
nodular basal cell carcinomas.  Liu et al. [42] and Choudry et al. [58] have also investigated EDTA and 
DFO respectively in humans, utilising matched skin lesion controls.  Lui et al. [42] found a promising 
and significant (p < 0.01) reduction in tumour depth in lesions treated with EDTA in combination 
with ALA-PDT.  Choudry et al. [58] however, could not detect any significant differences in surface 
fluorescence between lesions co-incubated with ALA +/- DFO.  Two clinical pilot studies of CP94 in 
combination with ALA or MAL-induced PDT have been conducted to date and have demonstrated 
the safety and feasibility of this treatment modification [12,67].  Although these latter clinical 
investigations were only designed to assess safety, enhancements in tumour clearance were 
observed both clinically and histologically when CP94 was included within the photosensitising 
cream.   
 
A more recent development in this field has been the design and synthesis of a new iron chelating 
PpIX prodrug, AP2-18 (Patent: Curnow, Wood & Perry; 06/03/14; PCT/GB2013/052297) [70].  This 
experimental drug essentially ester links ALA to CP94 to aid their co-delivery to cells in equimolar 
amounts.  This experimental study therefore aims to compare the effect of this new combined iron 
chelating PpIX prodrug in the MRC5 and A431 cell types previously studied with CP94 with success 
[53].  The levels of PpIX fluorescence produced by AP2-18 as well as the PDT effects (as assessed by 
the lactate dehydrogenase and neutral red assays) produced within each cell type following 
subsequent irradiation have therefore been compared against the established PpIX precursors ALA 
and MAL administered either alone, or in combination with, the most effective known iron chelating 
agent for this purpose, CP94. 
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MATERIALS AND METHODS 
 
All media, reagents and chemicals were obtained from Sigma-Aldrich Chemicals Company (Poole, 
UK) unless otherwise stated.   
 
Cell culture 
Human fetal lung fibroblasts (MRC-5) and human epithelial squamous carcinoma cells (A431) were 
purchased from the European Collection of Cell Cultures (ECACC, Wiltshire, UK).  MRC-5 and A431 
cells were cultured in Eagle’s minimum essential medium (EMEM) supplemented with 10% fetal 
bovine serum (FBS), 2% (200 mM) L-glutamine and 2% (200u ml-1) penicillin and (200µg ml-1) 
streptomycin solution.  All cell culture procedures were conducted in a class II laminar flow cabinet 
using aseptic conditions.  The cells were grown in an incubator at 37oC and 5% CO2 and passaged as 
required.  These two cell types were specifically selected for this investigation as they were the only 
cell types from a range that we have previously studied [53], where we observed iron chelation 
significantly enhancing the effects of PpIX-PDT. 
 
Test compound preparation 
100 mM stock solutions of each test compound (ALA, MAL, CP94 (Professor Hider, King’s College 
London, UK) and AP2-18 (Drs Wood & Perry, University of Exeter, UK)) were prepared by dissolving 
the individual powders in PBS.  These were stored at 5oC for up to one month.  Further dilution to 
the final concentrations employed (500 µM and 1000 µM) for each compound was achieved using 
colourless modified EMEM (i.e. without phenol red; Fisher Scientific, UK) on the day of each 
experiment.  These specific concentrations were selected as previous experimentation [53] has 
indicated that similar quantities of PpIX are produced by 500 µM ALA and 1000 µM in these 
particular cell types when incubated over the time period of interest (3-6 hours). 
 
Cell preparation and test compound incubation 
A cell count was performed utilising trypan blue before seeding the cells into 96 well plates (Corning, 
flat clear-bottom, black (to prevent fluorescence bleeding into neighbouring wells)) at a density of 
4.3 x 104 cells per well.  Cell viability as determined by the trypan blue exclusion method was found 
to be >98% for all experiments.  The cells were then incubated overnight (37oC; 5% CO2) and had 
reached confluence the next day, ready for experimentation.  The medium was then removed, the 
adherent cells washed three times with phosphate-buffered saline (PBS) and 100 µl of the test 
solutions (ALA ± CP94, MAL ± CP94 or AP2-18) introduced as required to the individual wells.  This 
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part of the procedure, as well as the rest of the experiment, was conducted under reduced ambient 
light levels within the laboratory to reduce the occurrence of PpIX photobleaching.  In each instance, 
two separate plates were set up exactly in parallel - one for irradiation and the other to act as a dark 
control. 
 
PpIX fluorescence quantification 
PpIX fluorescence was measured using the SkanIt software on the VarioskanFlash plate reader 
(Thermo Fisher Scientific, Finland).  Measurements were taken every hour for 6 hours to cover the 
drug-light period usually adopted within clinical practice, with 405 ± 12 nm excitation and 635 ± 12 
nm emission filters in place to measure the PpIX fluorescence produced.  This experimentation was 
proceeded by the production of a standard curve utilising synthetic PpIX (data not shown; see also 
[53]).  Between measurements, plates were kept in the incubator (37oC; 5% CO2) with care being 
taken throughout to avoid any PpIX photobleaching. 
 
Light irradiation 
Immediately following the PpIX fluorescence measurement after six hours, the treatment solutions 
were removed from all the wells and replaced with 150 µl modified EMEM plus 5% FBS.  This step 
ensured that the subsequent cell death observed following irradiation was solely due to the PpIX 
accumulated inside the cells themselves.  The irradiation plate was then placed 5 cm below an 
Aktilite CL16 LED array (Galderma, UK) and irradiated with 30 J/cm2 of red light (635 ± 2 nm; 75 
mW/cm2).  The other parallel plate was kept in the dark, out of the incubator, for the same amount 
of time to act as a dark control.  The duration of this irradiation period, with this particular light 
source, was just under 8 minutes.  Following irradiation, a final PpIX fluorescence reading was 
undertaken prior to incubating the cells overnight (37oC; 5% CO2).   
 
Quantification of PDT Effectiveness 
The cytoTox 96® assay (Promega, UK) was utilised to determine the PDT effect of each set of 
parameters on each cell type.  This assay colorimetrically measures the amount of lactate 
dehydrogenase (LDH) released by lysed cells into the medium, by supplying lactate, NAD+ and a 
tetrazolium salt (iodonitrotetrazolium violet; INT) as substrates in the presence of the diaphorase.   
The amount of the red formazan product generated by this enzymatic reaction was proportional to 
the amount of LDH released and therefore the number of dead cells [71].  Specifically, 12 hours 
following irradiation the plates were centrifuged (200 g for 5 minutes) and 50 µl of each well’s 
supernatant transferred to a clean plate.  50 µl cytoTox 96® reagent was added to each new well and 
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the whole plate was kept in the dark at room temperature for 30 minutes before the reaction was 
terminated.  A plate reader (VarioskanFlash, Thermo Fisher Scientific, Finland) was employed to read 
absorbance at 490 nm.  In addition to the test compounds, each plate also contained three wells 
with completely lysed cells to act as a (positive) maximum LDH release control, so that the 
percentage cell death could be derived.   
 
These LDH observations of PDT effectiveness were also confirmed using the neutral red assay, which 
measures the ability of intact cells to take up neutral red via active transport mechanisms and 
incorporate it within their lysosomes.  Subsequently, following washing, the viable cells in each 
sample can release this bound dye (under acidified-extracted conditions) for quantification to 
determine the total number of viable cells present [72].  Specifically, 50 µL colourless EMEM plus 7.5 
µL neutral red solution was added to each well of the original plates following their centrifugation 
and supernatant removal above and incubated for one hour (37oC; 5% CO2).  The wells were then 
washed once with 150 µL PBS and 150 µL solubilisation solution added per well and left for 10 mins 
before pipetting up and down gently (to release all neutral red).  Each plate also included three wells 
with completely lysed cells to act as a positive control.  A plate reader (VarioskanFlash, Thermo 
Fisher Scientific, Finland) was then employed to read the absorbance generated at 540 nm to 
determine the number of cells that survived the PDT treatment.   
 
Statistical analysis 
Each experiment was conducted in triplicate (three separate wells) on three different days.  Each 
plate also contained (blank) control cells incubated without the test compounds, which were utilised 
to remove background fluorescence from the readings of the test compounds detailed above.  
Results were presented as mean normalised PpIX fluorescence, percentage cell death (LDH assay) 
and percentage cell survival (neutral red assay) ± standard error (SE).  Statistical significance 
(indicated at the p < 0.05 level) was determined using an independent samples analysis of variance 
(ANOVA) to compare the differences in PpIX fluorescence produced by the different test compounds 
at each time point.  A repeated measures ANOVA was also conducted to compare the overall 
difference in PpIX fluorescence produced by ALA and MAL.   
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RESULTS 
 
Baseline comparison of ALA alone versus MAL alone 
PpIX fluorescence was measured hourly for 6 hours after treating the cells with 500 or 1000 µM ALA 
or MAL.  PpIX fluorescence was observed to increase over time as expected for both cell types 
investigated.  The normal lung fibroblasts (MRC5) were noted to accumulate more PpIX in arbitrary 
units compared to the squamous cell carcinoma cells (A431) (Figure 1a and 1b).  For both cell types 
investigated here, 1000 µM ALA consistently produced the highest level of fluorescence observed, 
followed by 1000 µM MAL and then 500 µM ALA in the normal fibroblasts (Figure 1a) but 500 µM 
ALA and then 1000 µM MAL in squamous carcinoma cells (Figure 1b), indicating that ALA was a more 
effective PpIX prodrug than MAL in this cell type.  Overall, the PpIX fluorescence produced by each 
congener were significantly different (p < 0.05) to one another in both cell types. 
 
As anticipated, the percentage of cell death in the irradiated (PDT) groups was observed to be 
significantly higher than the corresponding non-irradiated (dark) controls with both cell types (Figure 
1c and 1d).  In the irradiated PDT group of both cell types, addition of the PpIX prodrugs ALA or MAL 
led to a significantly increased cell death compared to the corresponding negative controls.  In the 
fibroblast PDT group, only 1000 µM MAL produced significantly higher cell death  compared to 500 
µM ALA (Figure 1c).  In the carcinoma PDT group however, 500 µM MAL produced significantly less 
cell death compared to 500 µM ALA or 1000 µM ALA, while 1000 µM MAL produced significantly less 
cell death than 1000 µM ALA but significantly more than 500 µM MAL (Figure 1d).  These measures 
of cell death obtained with the LDH assay were therefore in close alignment with the PpIX 
fluorescence measurements observed above (i.e. bigger PDT effects generally observed in the 
groups determined to have the highest PpIX levels prior to irradiation). 
 
PDT effectiveness was further confirmed using the neutral red assay, which determined cell survival.  
The results supported that recorded with the LDH assay above, with significantly fewer cells being 
able to incorporate neutral red in their lysosomes being observed in the PDT group than the (dark) 
control group in all cases (Figure 1e and 1f).  In the squamous carcinoma PDT groups, ALA was also 
observed to be a more effective photosensitising agent in this cell type than MAL.  Administration of 
500 µM MAL was associated with the highest percentage of cell survival observed after irradiation 
(i.e. lowest cell kill) when compared to the other test compounds (Figure 1f) and so was the least 
effective variable investigated in this particular series of experimentation.   
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Comparison of ALA alone, ALA ± CP94 and AP2-18 
In normal fibroblasts, addition of CP94 to ALA at both doses investigated was observed to increase 
PpIX fluorescence slightly but only with statistical significance at 1 hour, and then also at 6 hours for 
the 500 µM group (Figure 2a and b).  Using the new combined iron chelating PpIX prodrug AP2-18 
however, significantly increased PpIX fluorescence compared to ALA alone for all six time points at 
both dose investigated (Figure 2a and 2b).  Furthermore, it was noted that utilising 1000 µM AP2-18 
also produced significantly more PpIX fluorescence than 1000 µM ALA and 1000 µM CP94 
administered separately as a combination for the first 5 hours (Figure 2b).  PpIX accumulation, as 
monitored via fluorescence, increased as expected over this time period in all experimental groups. 
 
Cell death of irradiated normal fibroblasts was observed with the LDH assay to be significantly higher 
than that of the non-irradiated cells, and to the negative control for both concentrations (Figure 2c 
and 2d).  In the 500 µM PDT group, AP2-18 produced significantly more cell death compared to ALA 
+ CP94 administered separately in combination (Figure 2c).   In the 1000 µM dosed groups, ALA + 
CP94 produced significantly less cell death compared to ALA alone in irradiated cells, while ALA + 
CP94 and AP2-18 produced significantly more cell death in the non-irradiated cells (Figure 2d).  
These findings mirror our previous work where enhancement of PpIX-induced PDT with an iron 
chelating agent was observed to be more effective at lower (more limited) doses of the PpIX 
precursor [73].  The neutral red assay results, although less discerning between the various 
parameters investigated, were supportive of the LDH assay findings and consistently confirmed 
significantly less cell survival  in the PDT groups than the control groups (Figure 2e and 2f), with 500 
µM ALA + 500 µM CP94 producing significantly more PDT effectiveness  compared to 500 µM ALA 
alone (Figure 2e).   
 
In squamous carcinoma cells, PpIX fluorescence also increased over time as expected.  Addition of 
CP94 to the ALA prodrug administration or alternatively utilising AP2-18, significantly increased PpIX 
fluorescence compared to ALA alone at all time points for all concentrations (Figure 3a and 3b).   
Thus demonstrating the beneficial effect of enhanced PpIX accumulation via the approach of using 
an iron chelating agent to augment this treatment modality.  Although PpIX fluorescence in ALA + 
CP94 treated cells with both doses investigated was observed to be slightly higher than that in AP2-
18 treated cells (Figure 3a and 3b), these differences were not found to be significant on statistical 
analysis. 
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Cell death as determined by the LDH assay was once again observed to be significantly higher in the 
PDT group compared to the control group as well as in the treated cells compared to the negative 
control in the PDT group for all concentrations with the squamous carcinoma cells (Figure 3c and 
3d).  AP2-18 produced significantly less cell death in this cell type (A431) compared to ALA + CP94 
administered separately in combination in the 500 µM PDT group, but significantly more cell death 
compared to ALA + CP94 in the control group (Figure 3c) indicating a minor increase in dark toxicity 
with these particular experimental parameters.  When utilising the higher dose of 1000 µM, no 
significant difference was observed between the cytotoxic effects of the different PDT groups as 
ascertained with the LDH assay.  The neutral red results indicated significantly lower cell survival 
(and therefore increased cell kill) in irradiated cells compared to non-irradiated cells (Figure 3e and 
3f) with no significant differences being observed between the different PDT groups in this cell type. 
 
Comparison of MAL alone, MAL ± CP94 and AP2-18 
In normal fibroblasts, addition of CP94 to MAL did not statistically increase the normal pattern of 
increasing PpIX fluorescence over 1 to 6 hours for both concentrations, except for at 1 hour in the 
1000 µM group (Figure 4a and 4b).  Using AP2-18 in this cell type however, significantly increased 
PpIX fluorescence compared to MAL alone at all time points for both concentrations, as well as when 
compared to MAL + CP94 at all time points considered with the 1000 µM dose parameter (Figure 4b) 
and all time points up to and including 5 hours with 500 µM administration (Figure 4a).  Thus 
indicating the enhanced effect of this new iron chelating PpIX prodrug on PpIX accumulation over 
and above that of MAL in this cell type. 
 
Normal fibroblast cell death determined via the LDH assay in irradiated cells was again significantly 
higher than within the non-irradiated groups and the negative control for all concentrations 
employed (Figure 4c and 4d).  In the 500 µM group, AP2-18 produced significantly more cell death 
when compared to MAL + CP94, but not to MAL alone (Figure 4c) and the MAL + CP94 group 
produced significantly less cell death than the MAL alone group on this occasion (Figure 4c).  In the 
1000 µM dosed PDT groups, MAL + CP94 also produced significantly less cell death compared to 
MAL alone, with MAL alone and AP2-18 not producing statistically different results from one 
another.  In the control group, both MAL + CP94 and AP2-18 produced significantly more cell death 
compared to the negative control (Figure 4d).  The corresponding neutral red results (Figure 4e and 
4f) verified that the PDT initiated on irradiation significantly decreased cell survival compared to the 
non-irradiated cells, and agreed with the LDH assay results.  No significant differences were 
observed between the cell kill achieved with MAL alone, MAL + CP94 or AP2-18 in this cell type. 
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In squamous carcinoma cells, addition of CP94 to MAL or using AP2-18 once again significantly 
increased the increasing PpIX fluorescence observed at all time points investigated compared to 
administration of MAL alone (Figure 5a and 5b).  PpIX fluorescence in AP2-18 treated cells compared 
to MAL + CP94 treated cells was observed to be significantly higher up to 1 hour in the 500 µM 
group (Figure 5a) and up to 2 hours in the 1000 µM group (Figure 5b) indicating that the rate of 
accumulation may have been slightly faster at the beginning of the drug-light interval with the new 
iron chelating PpIX prodrug, AP2-18. 
 
Cell death in irradiated squamous carcinoma cells using the LDH assay was found to be significantly 
higher compared to the non-irradiated cells, as well as to the negative control in the PDT group for 
all concentrations employed (Figure 5c and 5d).  However, both MAL + CP94 and AP2-18 produced 
significantly more cell death compared to MAL alone in the PDT groups for all concentrations (Figure 
5c and 5d), indicating that the approach of iron chelation was particularly advantageous when 
considering undertaking MAL-PDT in this skin cancer cell type.  AP2-18 produced significantly less 
cell death compared to MAL + CP94 in the 500 µM PDT group and significantly more cell death than 
MAL alone in the control group (Figure 5c).  The neutral red results verified the LDH  findings with 
MAL + CP94 and AP2-18, indicating the production of significantly lower cell survival (and thus more 
cell kill) compared to MAL alone for all concentrations (Figure 5e and 5f).  Furthermore, these 
experimental groups (MAL + CP94 versus AP2-18) were not found to produce any significantly 
different effects to one another, despite their different compositions.  
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DISCUSSION 
 
PDT using topical prodrugs requires the conversion of these PpIX precursors into the active 
photosensitiser [74].  The highest dose of ALA investigated here (1000 µM) consistently produced 
the highest level of PpIX fluorescence observed, indicating that ALA was a more effective PpIX 
prodrug than MAL in both the cell types investigated (Figure 1a and 1b).  This supports our previous 
findings where MAL-treated cells accumulated less PpIX than cells treated with the same 
concentration of ALA [55].  Furthermore the cytotoxicity findings of cell death quantified with the 
LDH assay (Figure 1c and 1d) were in close alignment with the PpIX fluorescence measurements (i.e. 
the greatest cell death was generally observed in the groups determined to have the highest PpIX 
levels prior to irradiation).  This agrees with the published findings of others, which have clearly 
demonstrated that increased PpIX accumulation leads to increased cell death post irradiation [56] 
and that the degree of cell damage produced depends on the amount of PpIX accumulated pre-
irradiation [30]. PDT effectiveness was further confirmed using the neutral red assay (Figure 1e and 
1f) and mirrored the results observed with the LDH assay.   
 
In the squamous carcinoma cells, ALA was again observed to be a more effective photosensitising 
agent than MAL in this experimental system, although generally it was noted that in this particular 
series of experimentation that the normal fibroblasts accumulated more PpIX, which resulted in 
bigger PDT cell kills on irradiation, than with the squamous carcinoma cells.  This contradicts some 
studies which suggest that cancerous cells make more PpIX than normal cells [56,75] because of 
their higher metabolic activity [54] and their altered iron metabolism [12].  PpIX is thought to 
accumulate to a greater degree and for a longer period of time in abnormal cells than normal cells 
[9].  De Souza et al however found that different cell lines produced different amounts of PpIX, most 
likely due to their differences in metabolism [54].  They found no correlation between cell 
proliferation and production of PpIX [54].  They suggest that PpIX production depends on the 
amount of enzymes present and this is associated with the number of mitochondria in each cell [54].  
This could help explain the difference in the levels of PpIX seen within the different cell types 
investigated here, as the MRC5 cells are larger than the A431 cells and would therefore contain 
many more mitochondria and hence more enzymes.   
 
These observations also reinforce the importance of including more than one cell type in 
experimental investigations of this nature, despite the compromise of having to include the normal 
lung fibroblasts alongside the more dermatological pertinent squamous cell carcinoma cells of 
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interest.  However, the other non-cancerous dermatological cell types we have investigated in the 
past [53], including normal skin fibroblasts (84BR) and keratinocytes (NHEK) only demonstrated 
minimal enhancement when investigating the iron chelating agents DFO and CP94 to augment ALA- 
or MAL-induced PDT.   Nonetheless, these findings will be beneficial if they translate into clinical 
practice, where avoidance of excessive damage to healthy cells in the treatment site is a desirable 
outcome. 
 
Adding equimolar concentrations of the iron chelator CP94 to the PpIX precursors increased PpIX 
accumulation in all cell types, but only significantly in the cancer cells.  This suggests that the iron 
chelator CP94 is most effective in the cancer cells where the haem biosynthesis pathway is more 
likely to be disrupted [7,76].  These findings support several studies that found that the addition of 
an iron chelator to a PpIX precursor increased PpIX accumulation and therefore fluorescence before 
irradiation [26,55-56], with MAL+CP94 treated cells producing the greatest enhancement of PpIX 
fluorescence in tumour cells [12,20].  This occurs because iron chelating agents reduce cellular levels 
of free iron, which is essential for haem formation to take place and thus this change in cellular 
environment, forces more PpIX to accumulate in the cell [54,56,76]. 
 
Although MAL is more lipophilic [6,26] and has a shorter time of photosensitivity [34] compared to 
ALA, which may convey an advantage in clinical application to skin lesions, after MAL absorption has 
occurred, the additional methyl group needs to be removed via cytosolic esterases before it can 
enzymatically converted into PpIX.  This adds an additional step to PpIX production from this PpIX 
precursor, which may reduce the rate of its PpIX accumulation slightly in experimental cellular 
systems as it will depend on specific cell types’ esterase capabilities.  Furthermore, it is known this 
small difference (the addition of a methyl group) also affects the route of drug entry into cells.  ALA 
is known to enter cells via active transport mechanisms via GABA transporters, whereas MAL is 
thought to enter cells via passive diffusion and non-polar amino acid transport [77].   
 
In the normal fibroblasts, using the new combined iron chelating PpIX prodrug AP2-18 not only 
significantly increased the PpIX fluorescence produced compared to ALA alone for all six time points 
at both doses  (Figure 2a and 2b), the highest dose explored (1000 µM AP2-18) also produced 
significantly more PpIX fluorescence than 1000 µM ALA and 1000 µM CP94 administered separately.  
This latter finding was unexpected and it is hypothesised that this was most likely due to the co-
delivery of the two component parts of the drug being delivered to the cell simultaneously before 
the action of cytosolic esterases separated them to affect PpIX accumulation more effectively, than 
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possible with the separately administered counterparts.  On irradiation however, only the increased 
PpIX levels produced by 500 µM AP2-18 translated into greater PDT effects than 500 µM ALA and 
500 µM CP94 administered separately (Figure 2c).  This particular finding supports our previous work 
where enhancement of PpIX-induced PDT with an iron chelating agent has been observed to be 
more effective at lower (and thus more limited) doses of the PpIX precursor, rather than at higher 
levels where PpIX may already be present in abundance [73].   
 
Although it is very difficult to translate experimental findings with adherent monolayers of a single 
cell type into the real world challenge of reaching the bottom of thicker nBCC tumours in clinic, it is 
clear from our fluorescence microscopy findings of this clinical situation [18] that PpIX levels at the 
base of these tumours can indeed be inadequate.  We therefore postulate that although there is 
light reaching this depth and there is molecular oxygen present, there is currently insufficient PpIX to 
cause cataclysmic oxidative stress and thus cell death in this situation with the current licensed 
dermatological PDT treatment regime [10].  However, as observed with CP94 in our clinical pilot 
studies both with ALA and MAL [67 and 12 respectively], the addition of an iron chelating agent can 
actually produce complete clinical clearance of nBCC with a single treatment cycle.  This is due to 
more PpIX being able to accumulate throughout the thickness of the tumour (NB: not more PpIX 
production, just greater accumulation of that PpIX produced from the same amount of precursor 
substrate), whilst the presence of an effective iron chelator temporarily prevents the conversion of 
PpIX to haem.  This approach (iron chelation) essentially makes the PpIX already being produced at 
the lower levels of thicker tumours have more utility at the time of irradiation.  The finding that the 
new combinational iron chelating PpIX prodrug AP2-18 may also be able to operate in a similar 
manner in this respect to CP94, particularly when PpIX levels are more limited is therefore 
encouraging and warrants further detailed study.   This is particularly important as CP94 is already in 
the public domain, which means it cannot be protected in a secure manner for clinical development.  
The new combined PpIX-precursor and siderophore, AP2-18 has therefore been specifically 
developed for this application and its synthesis patented [70] to resolve this issue, so that the 
enhancement of PpIX-induced PDT via iron chelation can be developed clinically for patient benefit.  
 
Incubation of normal fibroblasts with AP2-18 was also found to significantly increase the PpIX 
fluorescence levels observed, when compared to MAL alone at all time points for both 
concentrations investigated, as well as compared to MAL + CP94 at all time points up to and 
including 5 hours with both doses considered (Figure 4).  This indicated the enhanced effect of this 
new form of iron chelating PpIX prodrug on PpIX accumulation over and above the action of MAL as 
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a PpIX-precursor for PDT in this cell type.  However no significant differences were observed 
between the PDT effect achieved with MAL alone, MAL + CP94 or AP2-18 in this cell type with the 
neutral red and LDH assays recording a mixed picture with 500 µM AP2-18 out-performing MAL + 
CP94 but not MAL alone and the MAL + CP94 groups at both concentrations producing significantly 
less PDT effects than the corresponding MAL alone groups. 
 
When this experimentation was repeated with the squamous carcinoma cells (Figure 3) both the 
addition of CP94 to ALA or AP2-18 administration significantly increased PpIX fluorescence 
compared to ALA alone at all time points for all concentrations in a similar manner but this increased 
accumulation failed to translate into greater PDT effectiveness over and above the already effective 
action of ALA alone in this cell type.  However when MAL was utilised as the PpIX precursor (Figure 
5), iron chelation using CP94 addition to MAL or alternatively AP2-18 administration not only 
significantly increased the increasing PpIX fluorescence observed at all time points investigated 
compared to administration of MAL alone but also produced significantly more cell death compared 
to MAL alone for both concentrations in a similar manner.  This indicates that the approach of 
supplementing with a pyridinone iron chelator was particularly advantageous when undertaking 
MAL-PDT in this skin cancer cell type.  CP94 is known to enter cells via simple diffusion [78] and this 
property of AP2-18 is yet to be determined but is likely to be similar to that of CP94.  The results of 
this experimentation also provide an indication that ubiquitous cytosolic esterases also manage to 
effectively separate the ALA and CP94 components that comprise AP2-18 successfully within the cell 
types employed here (in a similar manner to the removal of the methyl group from MAL), so that the 
normal but elevated biochemical processes can ensue.  
 
PpIX is produced in the mitochondria, but it can subsequently localise within cell membranes and 
the cytosol [5, 79], leading to apoptosis or necrosis respectively [8].  We previously found that cell 
death following PDT resulted from low amounts of apoptosis but high amounts of necrosis, possibly 
as a result of huge mitochondrial damage [20].  However, the main type of cell death following PDT 
is still to be established and heavily depends on the treatment parameters employed [20].  For this 
study, the lactate dehydrogenase assay was used to measure cell death.  This assay measures LDH 
release, which occurs following the rupture of the cell membrane.  This process usually occurs during 
necrosis.  However, the cells may have also undergone some form of programmed cell death, which 
can occur without membrane rupture and hence LDH detection via this method.  This aspect should 
therefore be investigated in more detail in future experimentation, despite validating the LDH assay 
findings with concurrent assessment of the number of living cells able to actively take up neutral red.  
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It is also important to note that AP2-18 as well as ALA, MAL and CP94 were all found to produce 
minimal dark toxicity throughout this study.  
 
In summary, generally iron chelation achieved via CP94 or AP2-18 administration significantly 
increased PpIX fluorescence.  ALA was again found to be a more effective PpIX-prodrug than MAL in 
A431 cells [55], corresponding with the lower PpIX accumulation observed with the latter congener.  
Addition of either iron chelator consistently increased PpIX accumulation but did not always convey 
an extra beneficial effect on PpIX-PDT cell kill in both cell types when using the already highly 
effective ALA treatment parameters and the highest doses considered but was highly beneficial in 
the skin cancer cells when compared with MAL administration alone.  AP2-18 was also at least as 
effective as CP94 + ALA/MAL co-administration throughout and significantly better than CP94 
supplementation at increasing PpIX fluorescence in MRC5 cells as well as at lower doses where PpIX 
accumulation was observed to be more limited.  PpIX accumulation as a measurement and indicator 
for successful PDT therefore appears to be highly dependent on the type of cells under investigation 
and as a result, future work should consider the effectiveness of this approach in other (non-
dermatological) tumour types, as the findings reported here may not be simply extrapolated to all 
other PpIX-PDT indications without corroborating evidence first being sought.  The new iron 
chelating PpIX prodrug AP2-18 was found however in this particular experimental model, to be at 
least as effective as CP94 co-administration with a PpIX-precursor and significantly better than CP94 
supplementation in certain circumstances.  However, before AP2-18 can be considered for future 
clinical study, confirmation of PpIX-PDT enhancement within in vivo models will be required, along 
with an analysis of its pharmacokinetics and metabolism, so that an optimal treatment protocol can 
be derived and thus investigated for clinical efficacy. 
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CONCLUSION 
 
PpIX fluorescence levels, as well as PDT effectiveness on irradiation were found to be significantly 
increased by pyridinone iron chelation, either via the addition of CP94 to the administration of a 
PpIX precursor or alternatively via the newly synthesised combined iron chelating PpIX prodrug, AP2-
18.  The effect of the latter compound appears to be at least equivalent to, if not better than, the 
separate administration of its constituent parts, particularly when employing MAL to destroy skin 
cancer cells.  AP2-18 therefore warrants further detailed analysis, as it may have the potential to 
improve dermatological PDT outcomes in specific clinical indications currently requiring 
enhancement. 
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FIGURE LEGENDS 
 
Figure 1:  Mean (± SE) PpIX fluorescence in (a) lung fibroblasts (MRC5) and (b) squamous cell 
carcinoma (A431), treated with 500 µM or 1000 µM of ALA or MAL for 6 hours.  Results also show 
corresponding percentages of LDH cell death of MRC5 (c) and A431 (d), and Neutral red cell survival 
of MRC5 (e) and A431 (f) respectively (± SE), of irradiated cells (PDT) compared to the non-irradiated 
(control) cells.  Statistically significance (ANOVA) to no light control = *, to positive/untreated control 
= +, to 500 µM ALA = Δ, to 1000 µM ALA = #, and to 500 µM MAL = ᴨ. * = p < 0.05, ** = p <0.01, and 
*** = p < 0.001. 
 
Figure 2:  Mean (± SE) PpIX fluorescence in lung fibroblasts (MRC5) treated with (a) 500 µM or (b) 
1000 µM of ALA ± CP94 or AP2-18 for 6 hours.  Results also show corresponding percentages  of LDH 
cell death (c) and (d), and Neutral red cell survival (e) and (f) respectively (± SE), of irradiated cells 
(PDT) compared to the non-irradiated (control) cells.  Statistically significance (ANOVA) to no light 
control = *, to positive/untreated control = +, to MAL = Δ, and to MAL ± CP94 = #. * = p < 0.05, ** = p 
< 0.01, and *** = p < 0.001. 
 
Figure 3:  Mean (± SE) PpIX fluorescence in squamous cell carcinoma cells (A431) treated with (a) 
500 µM or (b) 1000 µM of ALA ± CP94 or AP2-18 for 6 hours.  Results also show corresponding 
percentages of LDH cell death (c) and (d), and Neutral red cell survival (e) and (f) respectively (± SE), 
of irradiated cells (PDT) compared to the non-irradiated (control) cells.  Statistically significance 
(ANOVA) to no light control = *, to positive/untreated control = +, to ALA = Δ, and to ALA ± CP94 = #. 
* = p < 0.05, ** = p < 0.01, and *** = p < 0.001.  
 
Figure 4:  Mean (± SE) PpIX fluorescence in lung fibroblasts (MRC5) treated with (a) 500 µM or (b) 
1000 µM of MAL ± CP94 or AP2-18 for 6 hours. Results also show corresponding percentages of LDH 
cell death (c) and (d), and Neutral red cell survival (e) and (f) respectively (± SE), of irradiated cells 
(PDT) compared to the non-irradiated (control) cells. Statistically significance (ANOVA) to no light 
control = *, to positive/untreated control = +, to MAL = Δ, and to MAL ± CP94 = #. * = p < 0.05, ** = p 
< 0.01, and *** = p < 0.001. 
 
Figure 5:  Mean (± SE) PpIX fluorescence in squamous cell carcinoma cells (A431) treated with (a) 
500 µM or (b) 1000 µM of MAL ± CP94 or AP2-18 for 6 hours. Results also show corresponding 
percentages of LDH cell death (c) and (d), and Neutral red cell survival (e) and (f) respectively (± SE), 
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of irradiated cells (PDT) compared to the non-irradiated (control) cells. Statistically significance 
(ANOVA) to no light control = *, to positive/untreated control = +, to MAL = Δ, and to MAL ± CP94 = 
#. * = p < 0.05, ** = p < 0.01, and *** = p < 0.001. 
 
